Amygdala size in amyotrophic lateral sclerosis without dementia: an in vivostudy using MRI volumetry
© Pinkhardt et al; licensee BioMed Central Ltd. 2006
Received: 08 July 2006
Accepted: 25 December 2006
Published: 25 December 2006
Evidence for extra-motor involvement in non-demented patients with amyotrophic lateral sclerosis (ALS) has been provided by multiple studies, in particular neuropathological studies have demonstrated neuronal loss in the amygdala. The aim of this study was to investigate possible alterations of amygdala volumes in vivo.
Twenty-two moderately disabled patients with definite ALS without cognitive or behavioural deficits and 22 age-matched healthy controls were included. Amygdala and total brain volumes were measured by region-of-interest-based volumetry in 3-D MRI.
A trend was observed with reduced amygdala size in the ALS group, since mean absolute and brain size-corrected amygdala volumes were 6.9% and 7.6% lower in the patient group compared to those in normal controls (P = 0.086 and P = 0.110), respectively.
Volumetrically identifiable alterations of the amygdala can be mapped in vivo and may be associated with psychopathological findings in later stages of ALS.
Amyotrophic lateral sclerosis (ALS) is characterised by a progredient degeneration of upper and lower motor neurons, but there is growing evidence for extra-motor involvement in non-demented patients with ALS that has been provided in neuropathological, neurophysiological, electrophysiological, and neuroimaging studies [1–4]. Not only is the association of motor neuron diseases (MND) with dementia of frontotemporal type well-established, but also the finding of frontotemporal cortex atrophy has been reported at autopsy of patients with the clinical diagnosis of MND without clinical signs of dementia . However, neuropathological extra-motor alterations are not limited to neocortical regions. Ubiquitin immunoreactive inclusions, as they are observed in lower motoneurons in ALS , were also found in neurons of the amygdala, in particular the baso-lateral aspect, in more than 30% of cases out of a group of non-demented MND patients . Moreover, animal experiments in transgenic mice of a functionally altered glutamate AMPA receptor subunit (GluR-B(N)) which can result in a phenotype characterized by a pattern of neurodegeneration and progressive motor decline resembling MND in humans, exhibited a selective loss of neurons in the amygdala . The amygdala is known to be an important element of the limbic system, so its involvement may be an important factor for behavioural changes or particularly for altered emotional responses in ALS without dementia, as they have been demonstrated in a previous study .
In vivo investigations of pathological changes using high-resolution magnetic resonance imaging (MRI) raise the possibility of analysing the topography of volume alterations. So far, there are no studies specifically investigating amygdala pathology in MND using modern MRI techniques. In this MRI-based volumetric study, we tested the hypothesis that there is amygdala volume loss in patients with ALS by a comparison with healthy subjects.
Patients and controls
The study was approved by the local ethics committee (Ethics Committee of the University of Ulm), and all patients gave their written informed consent. Twenty-two patients with a clinical diagnosis of ALS according to the revised El Escorial criteria for the diagnosis of ALS  were included in the study (mean age 58 ± 9 years; 19 men, 3 women). The MRI data of the same patients and the controls had been previously analysed by automated techniques (voxel-based morphometry) in which no volume alterations of the amygdala were observed in a whole brain study at group level . All patients had clinical evidence of upper motor neuron degeneration as well as clinical and electrophysiological evidence for lower motor neuron involvement in at least three regions, as shown by independent investigations by two experienced neurologists at the time of scanning. Nineteen patients had limb onset, three had bulbar onset. The mean time between onset of motor symptoms (as assessed by patients' self-reports) and MRI scanning was 2 years. The ALS Functional Rating Scale  ranged from 20 to 40 (median 30). A neuropsychological test battery was performed including tests for frontal functions (Regensburg Fluency Test for verbal fluency or 5-Point Fluency Test for design fluency), Symbol Digit Modalities Test, Wisconsin Card Sorting Test (PC version), Doors Test, and Beck's Depression Inventory (BDI). Here, design fluency, planning and conceptual formation, attention, and visual memory were unimpaired in all patients, verbal fluency was normal in all but two patients. The patients scored a mean of 7 (range 4–16) in BDI, only two patients fulfilled the criteria of mild depression; thus, none of the patients met the cutoff for moderate depression of 18. There were no behavioural abnormalities in all patients.
A control cohort was set up by acquiring MRI data from an age-matched group of 22 healthy subjects (mean age 59 ± 11 years; 17 men, 5 women) by use of the same scanning protocol. All volunteers were neurologically and neuropsychologically normal (as shown by the use of the same test battery), none had any history of neurological or psychiatric disease or other medical conditions.
Data acquisition and processing
High-resolution MRI was acquired in all subjects on the same 1.5 Tesla clinical scanner with a standard quadrature headcoil (Siemens, Erlangen, Germany). Three-dimensional data sets of the whole brain were collected using a T1 weighted magnetisation prepared rapid acquisition gradient echo (MP-RAGE) sequence, consisting of 160 to 180 sagittal partitions depending on head size. The acquisition parameters were as follows, repetition time 9.7 ms; echo time, 3.93 ms; flip angle, 15°; matrix, 256 × 256 mm2; field of view, 250 mm.
The rater was trained in volume-of-interest-based analysis of MRI and was blinded to the subject grouping. Intrarater reliability was tested by repeated measurements of a subset of 10 subjects.
Patient and control groups were compared using the t-test within the Statistical Package for the Social Sciences software (SPSS, Version 12.0, Chicago, IL, USA). A two-sided level of significance of 0.05 was defined. The intrarater reliability was assessed by four different methods: (i) the ratio of measured standard deviations to average amygdala volumes (coefficient of variation), (ii) the coefficient of repeatability, Cr , (iii) an intraclass correlation coefficient, and (iv) the similarity index (SI) in order to compute measures of overlap of the ROIs according to Heckemann et al. [17, 18].
Synopsis of volumetric findings in ALS patients and controls (mean values ± SD).
right amygdala volume [cm3]
left amygdala volume [cm3]
total amygdala volume [cm3]
proportion of amydala to total brain volume [× 10-3]
1.487 ± 0.262
1.526 ± 0.312
3.014 ± 0.534
2.69 ± 0.609
1.628 ± 0.258
1.610 ± 0.288
3.239 ± 0.512
2.91 ± 0.488
P = 0.043
P = 0.186
P = 0.086
P = 0.110
For intrarater reliability, the coefficient of variation was 8.5%. The coefficient of repeatability (Cr) was 224 mm3, i.e. 14% of the overall mean, and the intraclass correlation coefficient was 0.65. All these values corresponded well to what has been reported in the literature . The mean SI was 0.793 ± 0.038 (range 0.736–0.849) for the right amygdala and 0.783 ± 0.029 (range 0.723–0.843) for the left amygdala. These values also corresponded well to previous studies .
The volumetric 3-D MRI-based measurements of amygdala demonstrated a trend for volume reduction in patients with clinically definite ALS, i.e. a mean decrease by 6.9% in absolute and 7.6% in corrected values. These data are in general accordance with autopsy studies which describe intraneuronal inclusion bodies and marked gliosis in the amygdala of ALS patients , although it has to be held that these histological changes might not influence volumes per se. Another reason for the apparent discrepancy between the marked amygdala alterations in neuropathological studies and the non-significant findings in MRI-based studies might be that the latter including the present one were performed in patients who were moderately disabled and that amygdala changes might be more pronounced in the later stages. The neuropathological findings seem to be more common in ALS patients with dementia , but they are not limited to these cases and are found in non-demented ALS patients as well . The lower volumes in ALS are obviously a subtle finding in in vivo studies which was only detected when amygdala volumes were specifically addressed – in contrast, there were no amygdala changes found in previous whole brain-based investigations in ALS using statistical comparisons of 3-D MRI data (voxel-based morphometry), neither in non-demented ALS patients  nor in patients suffering from ALS/frontotemporal lobar degeneration complex . The trend for lower amygdala volumes is the more remarkable since there was no global atrophy of the ALS patients' brains found here (i.e., the total brain volumes did not differ from controls), opposite to previously used automated techniques . These discrepant findings might be explained by the basic methodological differences in global atrophy assessment between the two studies. In the present study, a volume-of-based approach was used on 3-D MRI data in native space to determine total brain volumes, for the purpose of correcting absolute amygdala volumes for global brain atrophy in a ratio of absolute volumes. In the previous study , brain parenchymal fractions (BPF) were investigated, i.e. size-normalised proportions of grey matter and white matter volumes to total intracranial volumes, calculated after pre-processing steps including statistical parametric mapping (SPM)-based spatial normalisation to standard space and automatic segmentation. Obviously the manual ROI delineation and automatic growing tool, performed in every tenth slice, within MRreg on the one hand and the SPM-based automatic processing of normalised data on the other hand produced different results with respect to the statistical significance of the comparison of ALS patients and controls.
The functional impact of the subtle structural amygdala abnormalities is hard to assess. The amygdala is believed to be important among other functions for evaluation of the emotional valence of stimuli in the early phases of sensory processing (assigning emotional significance to specific sensory input ), linkage of perceptual representation to emotional memories and regulation of autonomic responses . In humans, the amygdala appears to be especially important for processing of emotional information in a social context . Affection and emotional processing in ALS is poorly understood beyond the general agreement that ALS patients do not develop a depressive disorder despite the severe impact of the disease on their lives. It has been demonstrated that emotional responses of ALS patients tend to be altered towards positive valence , and it seems a plausible concept that alterations of the amygdala might be involved in this process.
Whether the volume reduction implies per se a loss of function of the amygdala or is just the morphological correlate of a generally altered function, remains unresolved. According to a PET study, a group of non-demented MND patients had a reduced regional cerebral blood flow in limbo-thalamic areas , indicative of functional decrease. With respect to cognitive abilities, the division of human behaviour into emotion and cognition is not as clear as previously suggested, and the finding that brain regions linked to executive function and working memory are correlated with amygdala response suggests one pathway by which complex cognitive manipulations of stimuli might influence the neural circuitry of emotion, so for instance an indirect communication between frontal cortical areas and amygdala exists . The involvement of amygdala volume decreases in dementia, even as a predictive factor, has been demonstrated, however, only for Alzheimer disease yet , but might be part of the ALS/dementia complex as well.
In summary, a trend for volume alterations of the amygdala in ALS could be observed in vivo by use of MRI volumetry. Additional investigations in later stage patients and patients with dementia and/or distinctive behavioural deficits promise further insights in the role of limbic system involvement within the multi-system degeneration process of MND.
The authors wish to thank Sonja Fuchs for her help with the acquisition of the MRI data. There were no external sources of funding for the study, for any author or for the manuscript preparation.
- Ludolph AC, Langen KJ, Regard M, Herzog H, Kemper B, Kuwert T, Bottger IG, Feinendegen L: Frontal lobe function in amyotrophic lateral sclerosis: a neuropsychologic and positron emission tomography study. Acta Neurol Scand. 1992, 85: 81-89.View ArticlePubMedGoogle Scholar
- Kato S, Oda M, Hayashi H, Kawata A, Shimizu T: Participation of the limbic system and its associated areas in the dementia of amyotrophic lateral sclerosis. J Neurol Sci. 1994, 126: 62-69. 10.1016/0022-510X(94)90095-7.View ArticlePubMedGoogle Scholar
- Abrahams S, Goldstein LH, Al-Chalabi A, Pickering A, Morris RG, Passingham RE, Brooks DJ, Leigh PN: Relation between cognitive dysfunction and pseudobulbar palsy in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 1997, 62: 464-472.View ArticlePubMedPubMed CentralGoogle Scholar
- Yoshida M: Amyotrophic lateral sclerosis with dementia: the clinicopathological spectrum. Neuropathology. 2004, 24: 87-102. 10.1111/j.1440-1789.2003.00544.x.View ArticlePubMedGoogle Scholar
- Leigh PN, Anderton BH, Dodson A, Gallo JM, Swash M, Power DM: Ubiquitin deposits in anterior horn cells in motor neurone disease. Neurosci Lett. 1988, 93: 197-203. 10.1016/0304-3940(88)90081-X.View ArticlePubMedGoogle Scholar
- Anderson VER, Cairns NJ, Leigh PN: Involvement of the amygdala, dentate and hippocampus in motor neuron disease. J Neurol Sci. 1995, 129 (Suppl): 75-78. 10.1016/0022-510X(95)00069-E.View ArticlePubMedGoogle Scholar
- Kuner R, Groom AJ, Bresink I, Kornau HC, Stefovska V, Müller G, Hartmann B, Tschauner K, Waibel S, Ludolph AC, Ikonomidou C, Seeburg PH, Turski L: Late-onset motoneuron disease caused by a functionally modified AMPA receptor subunit. Proc Natl Acad Sci USA. 2005, 102: 5826-5831. 10.1073/pnas.0501316102.View ArticlePubMedPubMed CentralGoogle Scholar
- Lulé D, Kurt A, Jürgens R, Kassubek J, Diekmann V, Kraft E, Neumann N, Ludolph AC, Birbaumer N, Anders S: Emotional responding in amyotrophic lateral sclerosis. J Neurol. 2005, 252: 1517-1524. 10.1007/s00415-005-0907-8.View ArticlePubMedGoogle Scholar
- Brooks BR, Miller RG, Swash M, Munsat TL: El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000, 1: 293-299. 10.1080/146608200300079536.View ArticlePubMedGoogle Scholar
- Kassubek J, Unrath A, Huppertz HJ, Lulé D, Ethofer T, Sperfeld AD, Ludolph AC: Global brain atrophy and corticospinal tract alterations in ALS, as investigated by voxel-based morphometry of 3-D MRI. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005, 6: 213-220. 10.1080/14660820510038538.View ArticlePubMedGoogle Scholar
- The ALS CNTF treatment study (ACTS) Phase I-II Study Group: The amyotrophic lateral sclerosis functional rating scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol. 1996, 53: 141-147.View ArticleGoogle Scholar
- Lemieux L, Wieshmann UC, Moran NF, Fish DR, Shorvon SD: The detection and significance of subtle changes in mixed-signal brain lesions by serial MRI scan matching and spatial normalization. Med Image Anal. 1998, 2: 227-242. 10.1016/S1361-8415(98)80021-2.View ArticlePubMedGoogle Scholar
- Tebartz Van Elst L, Baeumer D, Lemieux L, Woermann FG, Koepp M, Krishnamoorthy S, Thompson PJ, Ebert D, Trimble MR: Amygdala pathology in psychosis of epilepsy: A magnetic resonance imaging study in patients with temporal lobe epilepsy. Brain. 2002, 125: 140-149. 10.1093/brain/awf008.View ArticlePubMedGoogle Scholar
- Watson C, Andermann F, Gloor P, Jones-Gotman M, Peters T, Evans A, Olivier A, Melanson D, Leroux G: Anatomic basis of amygdaloid and hippocampal volume measurement by magnetic resonance imaging. Neurology. 1992, 42: 1743-1750.View ArticlePubMedGoogle Scholar
- Cendes F, Andermann F, Gloor P, Evans A, Jones-Gotman M, Watson C, Melanson D, Olivier A, Peters T, Lopes-Cendes I: MRI volumetric measurement of amygdala and hippocampus in temporal lobe epilepsy. Neurology. 1993, 43: 719-725.View ArticlePubMedGoogle Scholar
- Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986, 1: 307-310.View ArticlePubMedGoogle Scholar
- Heckemann RA, Hajnal JV, Aljabar P, Rueckert D, Hammers A: Automatic anatomical brain MRI segmentation combining label propagation and decision fusion. Neuroimage. 2006, 33: 115-126. 10.1016/j.neuroimage.2006.05.061.View ArticlePubMedGoogle Scholar
- Zijdenbos AP, Dawant BM, Margolin RA, Palmer AC: Morphometric analysis of white matter lesions in MR images: method and validation. IEEE Trans Med Mag. 1994, 13 (4): 716-724. 10.1109/42.363096.View ArticleGoogle Scholar
- Tebartz van Elst L, Woermann FG, Lemieux L, Thompson PJ, Trimble MR: Affective aggression in patients with temporal lobe epilepsy: a quantitative MRI study of the amygdala. Brain. 2000, 123: 234-243. 10.1093/brain/123.2.234.View ArticleGoogle Scholar
- Chang JL, Lomen-Hoerth C, Murphy J, Henry RG, Kramer JH, Miller BL, Gorno-Tempini ML: A voxel-based morphometry study of patterns of brain atrophy in ALS and ALS/FTLD. Neurology. 2005, 65: 75-80. 10.1212/01.wnl.0000167602.38643.29.View ArticlePubMedGoogle Scholar
- Wand G: The anxious amygdala: CREB signaling and predisposition to anxiety and alcoholism. J Clin Invest. 2005, 115: 2697-2699. 10.1172/JCI26436.View ArticlePubMedPubMed CentralGoogle Scholar
- Aggleton JP: The amygdala. 2000, New York, OxfordGoogle Scholar
- van Rijn S, Aleman A, Swaab H, Kahn RS: Neurobiology of emotion and high risk for schizophrenia: role of the amygdala and the X-chromosome. Neurosci Biobehav Rev. 2005, 29: 385-397. 10.1016/j.neubiorev.2004.11.005.View ArticlePubMedGoogle Scholar
- Kew JJ, Goldstein LH, Leigh PN, Abrahams S, Cosgrave N, Passingham RE, Frackowiak RS, Brooks DJ: The relationship between abnormalities of cognitive function and cerebral activation in amyotrophic lateral sclerosis. A neuropsychological and positron emission tomography study. Brain. 1993, 116: 1399-1423.View ArticlePubMedGoogle Scholar
- Phelps EA: Emotion and cognition: Insights from studies of the human amygdala. Annu Rev Psychol. 2006, 57: 27-53. 10.1146/annurev.psych.56.091103.070234.View ArticlePubMedGoogle Scholar
- den Heijer T, Geerlings MI, Hoebeek FE, Hofman A, Koudstaal PJ, Breteler MM: Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people. Arch Gen Psychiatry. 2006, 63: 57-62. 10.1001/archpsyc.63.1.57.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2377/6/48/prepub